E. Bechthold, L. Grey, E. Diamant, J. Schmidt, R. Steigerwald, F. Zhao, K. B. Hansen, L. Bunch, R. P. Clausen, B. Wünsch
Forschungsartikel (Zeitschrift) | Peer reviewedThe GluN2C subunit exists predominantly, but not exclusively in NMDA receptors within the cerebellum. Antagonists such as UBP1700 and positive allosteric modulators including PYD-106 and 3-acylamino-2-aminopropionic acid derivatives such as UA3-10 ((R)-2-amino-3-{[5-(2-bromophenyl)thiophen-2-yl]carboxamido}propionic acid) represent promising tool compounds to investigate the role of GluN2C-containing NMDA receptors in the signal transduction in the brain. However, due to its high polarity the bioavailability and CNS penetration of the amino acid UA3-10 are expected to be rather low. Herein, three ester prodrugs 12a-c of the NMDA receptor glycine site agonist UA3-10 were prepared and pharmacokinetically characterized. The esters 12a-c showed higher lipophilicity (higher logD7.4 values) than the acid UA3-10 but almost the same binding at human serum albumin. The acid UA3-10 was rather stable upon incubation with mouse liver microsomes and NADPH, but the esters 12a-c were fast hydrolyzed to afford the acid UA3-10. Incubation with pig liver esterase and mouse serum led to rapid hydrolysis of the esters 12a-c. The isopropyl ester 12c showed a promising logD7.4 value of 3.57 and the highest stability in the presence of pig liver esterase and mouse serum. These results demonstrate that ester prodrugs of UA3-10 can potentially afford improved bioavailability and CNS penetration.
Bechthold, Elena Berenike | Professur für Pharmazeutische Chemie (Prof. Wünsch) |
Grey, Lucie | Professur für Pharmazeutische Chemie (Prof. Wünsch) |
Steigerwald, Ruben | Professur für Pharmazeutische Chemie (Prof. Wünsch) |
Wünsch, Bernhard | Professur für Pharmazeutische Chemie (Prof. Wünsch) |